Compare DOX & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOX | KRYS |
|---|---|---|
| Founded | 1982 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 7.8B |
| IPO Year | 1998 | 2017 |
| Metric | DOX | KRYS |
|---|---|---|
| Price | $66.41 | $261.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $92.33 | ★ $297.60 |
| AVG Volume (30 Days) | ★ 1.0M | 217.1K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.45% | N/A |
| EPS Growth | N/A | ★ 128.00 |
| EPS | N/A | ★ 6.84 |
| Revenue | N/A | ★ $389,130,000.00 |
| Revenue This Year | $4.48 | $39.88 |
| Revenue Next Year | $3.76 | $34.38 |
| P/E Ratio | ★ $13.65 | $38.23 |
| Revenue Growth | N/A | ★ 33.94 |
| 52 Week Low | $63.33 | $123.03 |
| 52 Week High | $94.61 | $298.30 |
| Indicator | DOX | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 48.15 | 53.83 |
| Support Level | $66.13 | $251.93 |
| Resistance Level | $70.61 | $263.75 |
| Average True Range (ATR) | 1.62 | 9.28 |
| MACD | 0.47 | 1.91 |
| Stochastic Oscillator | 86.70 | 80.82 |
Amdocs Ltd is a provider of software and services to communications, entertainment, and media service providers. The Company operates in a single segment and designs, develops, markets, supports, implements, and operates open and modular cloud offerings. Its portfolio includes solutions across digital business systems and legacy business and operational support systems, supporting multiple lines of business such as wireless, broadband, cable, fiber, satellite, and digital services. The Company leverages artificial intelligence to support digital transformation, cloud adoption, and intelligent network automation. Geographically, it derives a majority of its revenue from North America and also operates in Europe and the rest of the world.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.